Editorial: Targeting ion channels for drug discovery: emerging challenges for high throughput screening technologies.

Competing Interests: LG and the University of Michigan have equity in Courage Therapeutics. TS was employed by Nanion Technologies Inc. and MR was employed by Albion Drug Discovery Services Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.